It was little surprise, after a Feb. 12 Cardiovascular and Renal Drugs Advisory Committee meeting that came down squarely against approval, that the FDA delivered a complete response letter (CRL) late Wednesday to The Medicines Co.'s (MDCO) new drug application (NDA) for the intravenous antiplatelet agent cangrelor to reduce thrombotic cardiovascular events.